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Background: Given the threat of resistance of human malaria parasites, including to artemisinin derivatives, new
agents are needed. Chloroquine (CQ) has been the most widely used anti-malarial, and new analogs (CQAns)
presenting alkynes and side chain variations with high antiplasmodial activity were evaluated.
Methods: Six diaminealkyne and diaminedialkyne CQAns were evaluated against CQ-resistant (CQ-R) (W2) and
CQ-sensitive (CQ-S) (3D7) Plasmodium falciparum parasites in culture. Drug cytotoxicity to a human hepatoma cell
line (HepG2) evaluated, allowed to calculate the drug selectivity index (SI), a ratio of drug toxicity to activity in vitro.
The CQAns were re-evaluated against CQ-resistant and -sensitive P. berghei parasites in mice using the suppressive
test. Docking studies with the CQAns and the human (HssLDH) or plasmodial lactate dehydrogenase (PfLDH)
enzymes, and, a β-haematin formation assay were performed using a lipid as a catalyst to promote crystallization
in vitro.
Results: All tested CQAns were highly active against CQ-R P. falciparum parasites, exhibiting half-maximal inhibitory
concentration (IC50) values below 1 μΜ. CQAn33 and CQAn37 had the highest SIs. Docking studies revealed the
best conformation of CQAn33 inside the binding pocket of PfLDH; specificity between the residues involved in
H-bonds of the PfLDH with CQAn37. CQAn33 and CQAn37 were also shown to be weak inhibitors of PfLDH.
CQAn33 and CQAn37 inhibited β-haematin formation with either a similar or a 2-fold higher IC50 value, respectively,
compared with CQ. CQAn37 was active in mice with P. berghei, reducing parasitaemia by 100%. CQAn33, −39
and −45 also inhibited CQ-resistant P. berghei parasites in mice, whereas high doses of CQ were inactive.
Conclusions: The presence of an alkyne group and the size of the side chain affected anti-P. falciparum activity
in vitro. Docking studies suggested a mechanism of action other than PfLDH inhibition. The β-haematin assay
suggested the presence of an additional mechanism of action of CQAn33 and CQAn37. Tests with CQAn34,
CQAn37, CQAn39 and CQAn45 confirmed previous results against P. berghei malaria in mice, and CQAn33, 39 and
45 were active against CQ-resistant parasites, but CQAn28 and CQAn34 were not. The result likely reflects
structure-activity relationships related to the resistant phenotype.
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Malaria remains a major public health problem, resulting
in 207 million cases and 627,000 deaths worldwide in
2012 [1]. There is no available vaccine, and the control of
the disease relies on the use of bed nets, other individual
protection against mosquito bites, and the successful drug
treatment of infected patients [2]. Presently, chemother-
apy has been hampered by the low sensitivity of the para-
site to most available anti-malarial drugs [3], including
artemisinin derivatives [4-6]. Resistance to chloroquine, in
the case of P. falciparum, is linked to mutations in the
P. falciparum chloroquine resistance transporter (pfcrt)
gene, which alters the transport and accumulation of
the drug in the digestive vacuole (DV) of the parasite
[7,8]. Plasmodium vivax resistance to CQ has been
described [9,10] and seems related to the intense malaria
morbidity in the Amazon region [11]. However, neither
CQ-R nor mutation markers were detected among
P. vivax in recent studies of 47 isolates from the West
Amazon, all from patients with non-severe malaria [12].
Chemical modifications of CQ have been used as a
powerful strategy to find new anti-P. falciparum agents
effective against drug-resistant parasites [13,14]. Structural
modifications of the alkyldiamine side chains have pro-
vided rather active compounds with decreased cross-
resistance to CQ [15] and with different structure-activity
relationships [16-18]. In the present work, six CQ analogs
(CQAns) that reduced parasitaemia in P. berghei-infected
mice [19], comprising diaminealkynes and diaminedialk-
ynes, were evaluated in vitro against CQ-R (W2 clone)
and CQ-S (3D7 strain) forms of P. falciparum parasites in
cultures. These CQAns were then reevaluated in mice
with CQ-sensitive or CQ-resistant P. berghei parasites.
The compounds with the best selectivity index, based
on drug cytotoxicity and activity in vitro, were evaluated
for the inhibition of β-hematin formation. To clarify the
possible mechanism of action of the CQAns evaluated
herein, docking studies were also performed based on
interactions between the CQAns and the plasmodial
lactate dehydrogenase (PfLDH) enzyme, a known target
of 4-aminoquinolines [20,21].
Methods
Synthesis of the molecules
Drug synthesis was performed as previously reported by
Da Silva et al. [22]. In brief, 4-alkyldiamino-7-chloroqui-
nolines were treated with 2 eq. of propargyl bromide
and K2CO3 in EtOH at 0°C for 72 h to produce the com-
pounds CQAn28, CQAn33, and CQAn34 at a 50% to
60% yield. The addition of 4 eq. of propargyl bromide
under the same conditions led to the production of the
compounds CQAn37, CQAn39, and CQAn45 at a 50%
to 60% yield (Figure 1). All the compounds were charac-
terized via one-dimensional nuclear magnetic resonance(1D-NMR), infrared (IR) spectroscopy, and melting point
(MP) assays, and the results were in accordance with data
in the literature [22].Cytotoxicity tests in vitro
A human hepatoma cell line (HepG2), originally re-
ceived from the University of Lisbon as a kind gift, was
cultured as described [23]. The cells were maintained
in RPMI 1640 medium (Sigma-Aldrich, ref 6504)
supplemented with 40 mg/L gentamicin and 10% heat-
inactivated foetal calf serum (FCS), and they were
maintained in a 5% CO2 atmosphere at 37°C. When
confluent, the cell monolayer was trypsinized, washed
with culture medium supplemented with 10% FCS,
counted, diluted (5 × 103 cells/well), placed in flat-bottom
96-well plates (Corning, Santa Clara, CA, USA), and in-
cubated for 18 h at 37°C to allow cell adhesion. The
compounds were added to the plates at concentrations
up to 1,700 μM, followed by incubation for an add-
itional 24 h, after which 20 μL (5 μg/mL) of 3-(4,5-di-
methylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT)
solution was added per well to evaluate drug cytotoxicity.
After 3 h, the supernatant was discarded, 100 μL of di-
methyl sulphoxide (DMSO) was added per well, and the
optical density was measured (SpectraMax340PC384,
Molecular Devices) at 570 nm (test) and 630 nm (back-
ground). Cell viability was expressed as the percentage
of the absorbance compared to the absorbance of the
untreated cells and subtracted from the appropriate
background measurement. The lethal drug dose for
50% of the cells (MLD50) was determined as described
[24] and was used to calculate the SI of the active com-
pounds, a ratio of the in vitro cell toxicity and activity
against P. falciparum (MLD50/IC50).Continuous cultures of P. falciparum
CQ-R P. falciparum parasites (W2 clone) [25] and CQ-S
(3D7 strain), originally received from New York Uni-
versity Medical School, were maintained in continuous
culture at 37°C in human erythrocytes (A+) using
complete medium (RPMI 1640 supplemented with 10%
blood group A+ human serum) changed daily [26]. Be-
fore tests with the molecules were performed, ring
stage parasites were synchronized using sorbitol [27]
and the parasitaemia and haematocrit were adjusted;
180 μL/well was added to 96-well microtiter plates
(Corning, Santa Clara, CA, USA) containing the diluted
compounds tested in triplicate. Drug activity was evalu-
ated in relation to control cultures with no drugs [28] and
was measured using the anti-histidine-rich protein II
(HRPII) test as described [29]. CQ was used in each test
as a control, and two to four experiments were performed
for each parasite strain.
Figure 1 Scheme of CQAns synthesis. a) 2 eq. propargyl bromide, K2CO3, EtOH, 0°C, 72 h, yield: 50 to 60%; b) 4 eq. propargyl bromide, K2CO3,
EtOH, 0°C, 72 h, yield: 50 to 60%.
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The anti-HRPII test was performed using P. falcip-
arum cultures adjusted for 0.05% parasitaemia and
1.5% haematocrit. The cultures were added to plates
containing the diluted drugs, followed by incubation
for 24 h under standard culture conditions [26]. The
contents of six wells with no drugs were harvested in
each test plate, pooled in microtubes, and frozen for
later use to measure the background parasite growth
as described [29]. After a 48 h incubation, the plates
were frozen and thawed twice, and 100 μL of lysed cells
from each well was added to a plate that had been pre-
coated overnight at 4°C with a primary anti-HRPII
monoclonal antibody (MPFM-55A ICLLAB®, USA) for
an immunoassay. Phosphate-buffered saline (PBS) con-
taining 0.05% Tween and 4% bovine serum albumin
was used for plate blocking (3 h at room temperature)
to avoid nonspecific antibody binding. After 1 h at room
temperature, the plate was washed, and 100 μL/well of a
secondary antibody solution (MPFG-55P ICLLAB®, USA)
was added, followed by incubation with 3,3′,5,5′-tetra-
methylbenzidine (TMB) chromogen (KPL, Gaithersburg,
MD, USA) in the dark. The reaction was stopped using
1 M sulfuric acid, and the absorbance was read
(450 nm) in a spectrophotometer (SpectraMax340PC384,
Molecular Devices). The anti-P. falciparum drug ac-
tivity was evaluated by comparing the parasite growth
in the drug-free control cultures, considered 100%
growth, with that in the drug test cultures. Using
curve-fitting software (Microcal Origin Software 5.0,
Inc.), a sigmoidal dose–response curve was generated,
enabling the determination of drug IC50 values. CQAns
presenting IC50 ≤ 1 μM were considered active; be-
tween 1–5 μM as partially active; and above 5 μM as
inactive.
Protocol for animal use in the anti-malarial tests
The protocol for animal use was approved by the Ethics
Committee for Animal Use (CEUA LW-23/13) of the
Oswaldo Cruz Foundation (Fiocruz). Only Swiss adult
female mice (20 ± 2 g weight) were used; they were
raised at the animal facilities at FIOCRUZ-Minas.Anti-malarial tests against P. berghei in mice
The suppressive test was performed as described [30]
using the P. berghei NK65 blood parasites, with some
modifications [31]. Briefly, the blood parasites were
maintained through weekly blood passages in mice. For
the experiments, groups of 20–30 mice were inoculated
with 1 × 105 infected erythrocytes. Approximately three
hours later, they were randomly distributed into groups
of five to six mice per cage, which were treated daily by
gavage for four consecutive days. All the compounds
were freshly diluted in 3% DMSO (Sigma-Aldrich) in
RPMI medium and were administered orally at doses of
25 mg/kg or 50 mg/kg. The control mice received the
drug vehicle. On days 5 and 7 after parasite inoculation,
blood was taken from the tail of each mouse and used
to prepare thin smears, which were methanol-fixed,
Giemsa-stained and examined microscopically to deter-
mine parasitaemia. The inhibition of parasite growth was
evaluated in relation to parasitaemia in the untreated
mice, which were considered to have 100% parasite
growth.
A P. berghei NK65 CQ-resistant strain maintained
at −70°C, selected by increasing doses of CQ, maintained
in mice under constant drug pressure (CQ 150 mg/kg)
[32] and stored at −70°C was also defrosted and used to
inoculate mice. When parasitaemic, the drug-resistant
parasites were subjected to serial blood passages main-
tained under CQ treatment with increasingly higher
doses, up to 150 mg/kg, then used for the experiments.
The mice were inoculated with 107 parasitized RBCs
using blood parasites from a donor with parasites resistant
to 150 mg/kg of CQ. Groups of five mice each were sepa-
rated 24 h after the parasite inoculation, then treated or-
ally with the test CQAn at doses of 25 or 50 mg/kg for
three consecutive days. Two control groups were used in
each experiment; one received CQ at 150 mg/kg and the
other was infected but treated with vehicle only (no
drugs). The inhibition of parasitaemia was evaluated as
described for the mice inoculated with the CQ-sensitive
parasites. A compound was considered active when it
inhibited parasitaemia more than 40% in relation to the
infected but vehicle-treated (no drugs) group.
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The assay was performed using a lipid as a catalyst to
promote crystallization [33]. Briefly, drug stock solutions
were prepared in DMSO and were used at a final concen-
tration of up to 30 mM. A haem stock (10 mM) was made
in DMSO and was diluted to 50 μM with 100 mM sodium
acetate (pH 4.8). A 10 mM 1-monooleoyl-rac-glycerol
(MOG) stock was made in ethanol and was sonicated be-
fore being added to a 50 μM haem stock to make 25 μM
MOG–50 μM haem in 100 mM sodium acetate (pH 4.8).
The 25 μM MOG–50 μM haem solution was sonicated
and added to the assay plate at 100 μL/well. The plates
were incubated at 37°C for 2 h to allow crystallization,
followed by the addition of 100 μl of 200 mM sodium bi-
carbonate (pH 9.1) to solubilize any remaining monomeric
haem. After incubation for 30 min at room temperature,
the amount of solubilized monomeric haem was deter-
mined by measuring the absorbance at 405 nm. Finally,
20 μl of 1 M sodium hydroxide was added to the plates to
dissolve any crystals that had been formed, and the
absorbance was read at 405 nm to determine the total
amount of haem present in each well. The inhibition of
haem crystallization was determined as a function of the
amount of monomeric haem that was not crystallized di-
vided by the total amount of haem present in the assay
mixture. The results are expressed as IC50 values based on
the percentage inhibition of β-haematin formation by the
CQAn.
Docking studies
The structures of the inhibitors studied were constructed
and optimized with the program Spartan 08 [34] using the
Merck Molecular Force Field (MMFF) method [35]. In
addition, the partial charges were calculated by single-
point energy calculations using the RM1 method [36].
The crystallographic structures of PfLDH and HssLDH
were downloaded from the Protein Data Bank [37] under
the codes 1LDG (resolution 1.74 Å and R factor = 0.197)
and 1IOZ (resolution 2.10 Å and R factor = 0.179),
respectively.
The program Molegro Virtual Docker® (MVD) [38] was
used for the docking studies, and the methodology used
was validated by re-docking. To observe possible interac-
tions of the ligands with the solvent present in the crystal,
35 water molecules from a cavity approximately 10 Å in
size were considered for the calculations with PfLDH,
whereas 54 molecules were considered for the calculations
with HssLDH. The docking region was restricted to a
radius of 15 Å from the centre of the cavity inside each
enzyme. The best ligand conformations inside the en-
zymes were chosen based on 100 runs for each ligand,
and considering the superposition to the structure of
NADH molecules present in the crystallographic struc-
tures combined with the best values for interaction energy,and for the H-bonds with water molecules and the resi-
dues of the active sites.
The volumes of the cavities of the NADH-binding
sites inside PfLDH and HssLDH were determined using
MVD® [38].
Results
Anti-P. falciparum activity and selectivity indexes of CQAns
All the CQAns were active in vitro against CQ-R P. fal-
ciparum parasites, exhibiting half-maximal inhibitory
concentration (IC50) values below 1 μM; the most ac-
tive molecule was CQAn33 (IC50 = 0.02 ± 0.001 μM).
Tested against the CQ-S parasites in parallel, CQAn34
and CQAn37 were active; CQAn33, CQAn39 and
CQAn45 were partially active; and CQAn28 was inactive
(Table 1).
Most of the CQAns were less toxic than CQ (MLD50 =
410.4±26.6 μM), with MLD50 values ranging from 943 to
1699 μM. The ratios of cytotoxicity to activity (selectivity
index, SI) of compounds CQAn37, CQAn33, CQAn39,
and CQAn34 were 24275, 7645, 5011, and 4101, respect-
ively, considering the CQ-R parasites. For CQAn28 and
CQAn45, the SI values were 2125 and 119, respectively;
and for CQ, the SI was 1080. Using CQ-S P. falciparum
parasites, none of the CQAns showed an SI higher than
CQ (SI = 5679). The highest SI values were exhibited by
CQAn34 (SI = 3144) and CQAn37 (SI = 2981); all the
other CQAns had SI values below 1500 (Table 2).
Anti-P. berghei malaria activity of the CQAns
All the compounds (CQAn28, CQAn33, CQAn34,
CQAn37, CQAn39, and CQAn45) that were tested in
mice with P. berghei caused between 73% and 100% inhib-
ition of parasitaemia after treatment with a 25 mg/kg oral
dose, compared with the untreated control group on day
5. On day 7, the parasitaemia inhibition reached 93%
(Table 3). CQ, used as a control, inhibited parasitaemia by
100% and 97% on days 5 and 7, respectively. The 50 mg/kg
dose of CQAn33, CQAn37 and CQ caused 100% inhibition
of P. berghei parasitaemia on days 5 and 7 after infection.
Two of the five mice receiving CQAn37 and all the mice
receiving CQ survived the infection at least 30 days after
the end of treatment; CQ cured the mice.
The CQAns were evaluated against a CQ-resistant
P. berghei strain (maintained by constant drug pressure
at a dose of 150 mg/kg daily until the last passage before
the test). The dose of 50 mg/kg was active for all the
CQAns on day 5. CQAn45 caused the highest parasit-
aemia reduction (63%), followed by CQAn39, CQAn33
and CQAn37, which reduced parasitaemia by 62%, 53%
and 47%, respectively. CQAn28 and CQAn34 were inactive
at 25 mg/kg. As expected, CQ at the highest tolerated
dose of 150 mg/kg was inactive against the CQ-resistant
P. berghei parasites in mice (Table 3).
Table 1 Activity of CQ and CQAn against P. falciparum (IC50) CQ-R (W2) or CQ-S (3D7) parasites
Molecule Chemical structure Anti-P. falciparum activity (IC50 in μM)*





































0.38±0.03 0.081 ± 0.019
*Average ± SD of the IC50 is based in two to four experiments performed with each parasite strain using anti-HRPII method.
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The inhibition of β-haematin formation was evaluated
for CQAn33 and CQAn37, the most active CQAns
against P. falciparum in vitro. The results showed that
CQAn33 inhibited β-haematin formation with an IC50
value similar to that of CQ, whereas CQAn37 inhibited
β-haematin formation at a concentration 2-fold higher
than that of CQ (Table 4).Docking studies and the mechanism of activity of the
CQAns
The root-mean-square deviation (RMSD) values obtained
through re-docking of the NADH structure inside each
crystal were lower than 2.00 Å in the case of PfLDH and
HssLDH (Tables 5 and 6). The cavities of the NADH-
binding sites inside PfLDH and the human lactate de-
hydrogenase enzyme (HssLDH) were determined to have
Table 4 Inhibitory concentrations of β-haematin formation
by chloroquine (CQ) and two analogs (CQAn)*
CQAn Exp Mean ± SD
1 2 3
33 4.7 3.0 5.6 4.3 ± 1.3
37 2.7 10.2 7.5 8.9 ± 3.8
CQ 0.6 2.0 5.0 3.5 ± 2.2
*Results expressed as IC50 in mM.
Table 2 Cytotoxicity of CQ and CQAn and SI on P.
falciparum parasites and therapeutic activity or selectivity
index (SI), a ratio between toxicity and activity
Molecule Cytotoxicity* MLD50 (μM) SI (MLD50/IC50)
HepG2 cells W2 (CQ-R) 3D7 (CQ-S)
CQAn28 1508.56 ± 344.50 2125 101
CQAn33 152.89 ± 12.86 7645 131
CQAn34 943.29 ± 73.15 4101 3144
CQAn37 1699.24 ± 10.07 24275 2981
CQAn39 ≥3207.08 5011 1342
CQAn45 1015.84 ± 42.97 1319 868
Chloroquine 410.4±26.6 1080 5,679
*Average ± SD of two to four experiments measured through
MTT-colorimetric assay.
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cavities were generated around the NADH structure
present inside the crystallographic structures. The results
suggest that the new CQAns studied have affinities for the
NADH-binding sites of PfLDH and HssLDH. These
compounds were able to dock and to establish highly
stable H-bonds with amino acids and water molecules
in the sites, as reflected by the highly negative total
intermolecular energy (IE) values (Tables 5 and 6). The
IE values were less negative inside HssLDH than inside
PfLDH.
Inside PfLDH, all the compounds (except CQAn45)
H-bonded to Asp53 and/or Thr97 plus water molecules
and displayed good (negative) H-bond energy values.
The intermolecular energies were ranked as follows: CQ >
CQAn39 > CQAn37 > CQAn33 > CQAn28 > CQAn45 >
CQAn34, with lower values than NADH. The highestTable 3 Anti-malarial activity of chloroquine (CQ) and its
analogs (CQAn) against P. berghei evaluated as
percentage reduction of parasitaemia on days after
inoculation with either a CQ sensitive or resistant strain
of the parasite*
CQAn CQ-Sensitive 25 mg/Kg CQ-Resistant 50 mg/Kg
Day 5 Day 7 Day 5 Day 7
28 94a 24a 0b 0
33 73a 57a 53 52
34 99 81 0b 0
37 100 93 47 33
39 95 92 62 30
45 88 50 63 51
CQ 100 97 0c 0c
*Reduction calculated in relation to control non-treated mice (100% of
parasite growth).
aAdapted from de Souza et al. [19]; all the compounds were used at 50mg/Kg,
except as indicated, in the dose of 25 mg/Kg because there was not enough
material for a higher doseb. In the case of CQ used as control in the test with
the resistant parasites, the dose used was 150 mg/Kg, which was totally
inactive, as expectedc.H-bond energy was observed for CQAn33 and the low-
est for CQAn45.
Most of the active-site residues of PfLDH involved in
H-bonds differed from those of HssLDH. Thus, the resi-
dues of PfLDH involved in H-bonds with CQAn33 and
CQAn37 were Thr97, Val138 and H20; and Asp53 and
H20, respectively. The residues of HssLDH for the same
molecules were Lys147, Ala146 and Asn116; and Gly15,
Asn116, Ala146 and Lys147, respectively.
To better understand the experimentally observed se-
lectivity, the electrostatic potentials of the NADH-binding
sites inside PfLDH and HssLDH were determined. The re-
sults showed differences in the binding pockets: inside the
PfLDH pocket, the electrostatic potential was totally
positive, whereas inside HssLDH, it was mostly negative,
as illustrated by CQAn33 docked inside both enzymes
(Figures 2 and 3).
Discussion
Although CQ-R is widespread, CQAns may help to over-
come the drug resistance, especially considering that it is
believed to be stage specific [39] and/or related to the
compound structure [15]. Indeed, various CQAns have
shown potent antiplasmodial activity against CQ-R P.
falciparum blood parasites [40-42]. Among the six CQAns
tested against P. falciparum in the present work, all exhib-
ited high activity against CQ-R parasites. CQAn28, 33, 37
and 39 were more potent against the CQ-R W2 clone than
against the 3D7 CQ-S parasites.
Variation in side chains seems to be a promising strat-
egy concerning the anti-malarial activity of CQAns, and
small changes in the spacer length can dramatically
affect the activity exhibited against CQ-S and CQ-R par-
asites [43]. Moreover, the presence of a terminal alkyne
seems important: CQAn33, which has a terminal alkyne,
showed an IC50 more than 10-fold higher than that of
CQ, which has no terminal alkyne.
The activity of 4-aminoquinolines involves their bind-
ing to haematin in the monomeric and dimeric forms,
inhibiting haemozoin formation and resulting in parasite
death [44]. The activity of CQ against P. falciparum also
involves interactions with the parasite enzyme PfLDH
[20], as shown by in silico studies with docking and mo-
lecular dynamics in the present work. The complex formed
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Figure 2 Interactions of CQAn33 inside HssLDH (left) and PfLDH (right). Water molecules inside the active sites are represented as red
spheres and H-bonds are shown as dotted green lines.
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inhibited PfLDH, as shown with other quinoline deriva-
tives [21].
In previous studies, RMSD values below 2.00 Å were
obtained for the plasmodial and human enzymes in re-
docking studies, which validates this methodology [45-47].
The intermolecular energy values for the CQAns were
higher than for CQ and NADH, showing that the mole-
cules studied here are weak inhibitors of PfLDH and sug-
gesting that they have a different mechanism of action.
CQAn33 and CQAn37, the molecules with the highest
SI in vitro, were also evaluated for their ability to inhibit
β-haematin formation. The results showed that CQAn33
inhibited β-haematin formation with an IC50 similar to
that of CQ, whereas CQAn37 exhibited an IC50 more
than 2-fold higher than CQ, which is in accordance with
this molecule being less active than CQAn33 against P.
falciparum. The results obtained for anti-P. falciparum
activity through the HRPII test showed a rather higher
activity of these CQAns in relation to CQ, suggesting an-
other mechanism of action than that related to haemozoinFigure 3 Surface representation of the binding sites of CQAn33 (NAD
negative charges, blue means positive charges and white means neutral.formation, such as apoptosis, autophagy or the inhibition
of P-glycoprotein-mediated transport. Metacaspase-like
proteins, which are related to caspases [48], have pre-
viously been shown to be inducers of apoptosis in P.
falciparum parasites exposed to CQ, with more intense
DNA fragmentation in CQ-R parasites than in CQ-S [49].
Autophagy-related proteins have been identified in P. fal-
ciparum [50,51]. Indeed, after CQ pressure, P. falciparum
parasites exhibited cytoplasmic vacuolization [52], a sign
of autophagic cell death [53] rather than of apoptosis.
A recent study showed that CQ significantly inhibited
P-glycoprotein-mediated transport [54], which is involved
in drug evasion in P. falciparum [55].
The highest and lowest H-bond energies were observed
for CQAn33 and CQAn45, respectively, a result that cor-
roborates the in vitro data showing that CQAn33 was the
most active molecule and CQAn45 the least active against
P. falciparum. Another difference is the residues of the
plasmodial and human enzymes involved in the H-bonds,
specific for CQAn33 and CQAn37; this result is consistent
with them having the highest SIs.H pockets) inside HssLDH (left) and PfLDH (right). Red means
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compounds’ tails inside PfLDH and HssLDH could be
explained by a large concentration of negative charges
due to the presence of the alkyne groups. This finding
suggests a better stabilization inside the more positive
pocket of PfLDH, which is caused by the size of the cav-
ity and increases drug specificity. Indeed, the smaller
cavity of PfLDH allows for better accommodation of the
ligands than inside HssLDH.
The most active CQAn in vitro also inhibited P. berghei
parasitaemia in mice, as shown in the present work and in
our previous studies with the same compounds [19]. An
increase in mouse survival resulting from treatment with
CQAn37 may well be a consequence of the alkyl side
chain altering the structure-activity relationship in the ter-
minal nitrogen [15], which may favor drug lipophilicity.
All the CQAns inhibited CQ-R P. berghei parasitaemia in
mice, translating the in vitro data, with the exception of
CQAn28 and 34, which is likely a result of metabolism
[13] or of the structure-activity relationships inherent to
the resistance phenotype, e.g., those related to pfcrt [7,56],
also in vivo [57].
The data reported herein highlight the use of CQAns
in malaria-endemic areas where drug resistance has been
reverted, i.e., sensitivity to CQ has reappeared [58]. CQ
is the most widely used anti-malarial drug worldwide [2]
due to its low cost, high efficacy and lack of toxicity. In
addition, the cost of a treatment course is rather low at
US$0.21 per patient [59]. The CQAns evaluated in this
study are generated in two steps using readily available,
inexpensive starting materials and can be produced in
good yields [22] at a cost expected to be as low as that
of CQ. Thus, the CQAns studied in the present work may
be produced at large scale to proceed in drug development
for anti-malarials, since they are promising alternatives for
malaria control.
Conclusions
Among the six CQAns tested in vitro, three were more
active than CQ, inhibiting 50% of P. falciparum growth
at low doses: CQAn33 (IC50 0.02 ± 0.001 μM), CQAn34
(IC50 0.23 ± 0.15 μM), and CQAn37 (IC50 0.07 ± 0.03 μM).
All were more active against the CQ-R (W2) parasites than
against the CQ-S (3D7) parasites, which suggests the ab-
sence of cross-CQ-R. In addition, the therapeutic indexes
(or SI) of all CQAns, with the exception of CQAn45, were
higher than that of CQ. Docking studies with CQAn33
and CQAn37 corroborated the outstanding anti-P. falcip-
arum activity observed herein and showed that CQAn33
had the highest H-bond energy with the plasmodial en-
zyme, indicating specificity for PfLDH. Additionally, they
showed that the CQAns are weak inhibitors of PfLDH,
suggesting a different mechanism of action. The inhibition
of β-haematin formation by CQAn33 and CQAn37 alsosuggested mechanisms of action other than those related
to haemozoin formation. The in vivo results with
CQAn34, CQAn37, CQAn39, and CQAn45 confirm
previous data showing their high anti-malarial activity.
Furthermore, the CQAns also inhibited the parasitaemia
caused by CQ-R P. berghei but CQ did not, translating
in vitro to in vivo data. However, CQAn28 and CQAn34
did not inhibit CQ-R P. berghei parasitaemia, what may be
a result of metabolism issues or structure-activity relation-
ships related to the resistant phenotype. Altogether,
the present results highlight the CQAns studied here
as promising anti-malarial agents due to their SI and
in vivo activity against malaria in mice.
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